Targeting Mechanisms That Promote Cancer Cell Survival: Genetic And Chemical Approaches To Unravel The Molecular Mechanisms That Drive Tumour Formation, Develop Novel Molecular And Chemical Probes, And Discover New Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$751,854.00
Summary
One in three of us are likely to die from cancers. Groundbreaking research, including those made by Prof Huang, has revealed some of the reasons why cancers arise. An attractive way to transform the poor outcomes for cancer patients is to develop better medicines based on findings made by the basic researchers. Prof Huang leads a team at WEHI, including chemists, focused on developing better drugs that exploit knowledge garnered through such basic research in order to improve cancer treatment.
Understanding How RUVBL1 And RUVBL2 Organise Chromosomes And Their Links To Disease
Funder
National Health and Medical Research Council
Funding Amount
$605,005.00
Summary
Our proposal will provide a deep mechanistic framework to inform both clinicians in diagnosis and management of RUVBL related diseases and also therapeutically, as industry looks to use these proteins as drug targets. The great excitement of RUVBL in translation has outpaced the gathering of vital knowledge underpinning the function; knowledge this proposal will provide for the first time.
Determining recurrence risk in breast cancer is crucial, as more than half of all recurrences occur after 5 years. However, optimal management of breast cancer is hampered by the challenges in finding rational preventative and predictive targets. Our vision is to find targets responsible for progenitor cell expansion, as candidates for prevention, and to find markers of relapse, to predict early versus late responders to therapy.
Understanding The Biological Regulation Of MLKL And Its Role In Necroptotic Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$656,979.00
Summary
Cell death is a normal process that permits the growth and defence of our vital tissues. One kind of cell death, necroptosis, is characterized by the swelling and bursting of cells. When cells ‘explode’ in this uncontrolled way they provoke an inflammatory response. This may be a factor behind illnesses ranging from colitis to cardiovascular disease. Understanding necroptotic cell death may pave the way for new therapies for those that suffer from these devastating conditions.
The Hippo pathway is a key regulator of tissue growth. It was first discovered in vinegar flies and plays a similar role in mammals. We aim to define the mechanism by which the different transcription factors in the Hippo pathway operate to control tissue growth. These studies will be performed in flies and mammalian cell culture. Our studies will shed light on how tissue growth is controlled, and have the potential to inform the way that we treat human cancers and tissue growth disorders.
Mechanisms For Regulation Of Myc Transcription And Cell Growth
Funder
National Health and Medical Research Council
Funding Amount
$645,347.00
Summary
We aim to use the animal model system, the vinegar fly, to investigate mechanism for cancer initiation. The fly has been studied for over 90 years and has proved an excellent genetic model for understanding the complex processes leading to abnormal cell growth, which is associated with the early stages of human cancer. The high level of conservation between fly genes and human cancer genes means these studies will provide novel insights into the genetic mechanisms underlying tumour formation.
The C-type Lectin Mincle Exemplifies A New Mode Of Sterile Inflammation In Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$609,237.00
Summary
This project investigates two of the life-changing cardiovascular events that most commonly impact on Australians today; Heart attack and Stroke. These diseases often leave individuals debilitated with a long recovery period, and for many people the event is fatal. We have shown that blocking the action of an immune component, "Mincle", reduces the inflammation associated with stroke, and improves recovery. This project looks at what Mincle does in brain and heart muscle, and why blocking Mincle ....This project investigates two of the life-changing cardiovascular events that most commonly impact on Australians today; Heart attack and Stroke. These diseases often leave individuals debilitated with a long recovery period, and for many people the event is fatal. We have shown that blocking the action of an immune component, "Mincle", reduces the inflammation associated with stroke, and improves recovery. This project looks at what Mincle does in brain and heart muscle, and why blocking Mincle protects cells from loss of oxygen.Read moreRead less
Elucidating The Tumour Suppressor Behaviour Of FUBP1 In Glioma
Funder
National Health and Medical Research Council
Funding Amount
$940,780.00
Summary
Treatment strategies for patients with invasive brain tumours are based on a WHO tumour grading system. This system does not account for differences within tumour types, although these can significantly affect treatment outcomes. This project aims to investigate new drug therapies for specific brain tumour types, and to identify new prognostic markers for these tumours. These studies will lead to more individualised treatments, which is critical to improving patient survival and quality of life.
Dissecting The Molecular Mechanisms During Reprogramming Of Different Somatic Cells Into Induced Pluripotent Stem Cells And The Plasticity Potential Of Their Intermediate Stages.
Funder
National Health and Medical Research Council
Funding Amount
$234,965.00
Summary
I am a biochemist interested in the molecular mechanisms involved in gene expression and how these processes govern cell identity. I use a combination of mouse models, biochemical techniques and bioinformatics to study the _reprogramming� of adult cells into embryonic stem-like cells and how this technology can be used to generate different cell types for use in cellular replacement therapies and drug screening.